Evidence map›Paper›PMID 41291902›Full record

ArticleJournal of experimental & clinical cancer research : CR2025

TIM-3 blockade reverses oncolytic vaccinia virus-induced DCs inactivation and T cells exhaustion to improve antitumor immunity and therapeutic efficacy.

Peipei Ye, Yi Wu, Xue Yang, Hui Wu, Yongming Xia, Gongqiang Wu, Gang Cheng, Weidong Sun, Junyu Zhang, Shibing Wang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Peipei Ye *Zhejiang Key Laboratory of Zero Magnetic Medicine, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, China.
Yi Wu *Department of Clinical Research Center, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, China.
Xue Yang *School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Hui WuSchool of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou, Zhejiang, China.
Yongming XiaDepartment of Hematology, Yuyao People's Hospital, Yuyao, Zhejiang, China.
Gongqiang WuDepartment of Hematology, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, Zhejiang, China.
Gang ChengDepartment of Stomatology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang, China.
Weidong SunDepartment of Hematology, Shaoxing Central Hospital, Shaoxing, Zhejiang, China.
Junyu ZhangDepartment of Hematology, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital, Lishui Hospital of Zhejiang University, Lishui, Zhejiang, China. zhangjunyu815@163.com.
Shibing WangZhejiang Key Laboratory of Zero Magnetic Medicine, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, China. wangshibing@hmc.edu.cn.
Xiangmin TongZhejiang Key Laboratory of Zero Magnetic Medicine, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, China. tongxiangmin@163.com.

Funding

Construction Fund of Key Medical Disciplines of Hangzhou-Laboratory Diagnostics 2025HZZD01Foundation of Science Technology Department of Hangzhou City 2024SZRYBC080002Foundation of Science Technology Department of Zhejiang Province LGD22H140003Foundation of Science Technology Department of Zhejiang Province LKLY25H160006Foundation of Science Technology Department of Zhejiang Province LKLY25H160010Key R&D Program of Hangzhou Science and Technology Bureau 20241203A11National Natural Science Foundation of China 82470182Shaoxing Health Science and Technology Project 2022KY080Zhejiang Health Science and Technology Project 2023KY385Zhejiang Provincial Traditional Chinese Medicine Science and Technology Plan Project 2023ZL733
6 · The paper itself

Abstract

Oncolytic vaccinia viruses (OVV) demonstrate the capacity to inflame the tumor microenvironment (TME) and elicit infiltrating tumor-specific T cells responses. However, OVV treatment paradoxically alters the cancer-immune equilibrium within tumors, attenuating anti-tumor immunity and necessitating a deeper understanding of the viral-induced immune landscape to optimize therapeutic potential. This study investigates the impact of single-domain antibody-armed OVs targeting TIM-3 on TME remodeling, aiming to overcome localized immunosuppression and enhance tumor responsiveness to immunotherapeutic interventions. We engineered a tumor-selective OVV vector encoding single-domain antibodies against murine (mNbTIM3) or human (hNbTIM3) TIM-3. The therapeutic efficacy of OVV-mNbTIM3 was evaluated across multiple murine cancer models, demonstrating that localized V

Indexed as

Dendritic CellsHepatitis A Virus Cellular Receptor 2NeoplasmsOncolytic VirotherapyOncolytic VirusesT-LymphocytesVaccinia virusAnimalsFemaleHumansMiceTumor MicroenvironmentHepatitis A Virus Cellular Receptor 2CD8+ t cellsDCsImmunotherapyOncolytic vaccinia virusesTIM-3

Identifiers

PMID41291902
PMCPMC12751143

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.